Skip Navigation


NDT Advance Access originally published online on June 17, 2006
Nephrology Dialysis Transplantation 2006 21(9):2352-2353; doi:10.1093/ndt/gfl316
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/9/2352    most recent
gfl316v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Casas, J. P.
Right arrow Articles by Smeeth, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Casas, J. P.
Right arrow Articles by Smeeth, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial Comment

Progression of renal disease—can we forget about inhibition of the renin–angiotensin system? Authors’ reply

Juan Pablo Casas1, Aroon D. Hingorani2, Raymond J. MacAllister2 and Liam Smeeth1

1 Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine and 2 Centre for Clinical Pharmacology, Department of Medicine, BHF Laboratories, University College London, UK

Correspondence and offprint requests to: Dr Juan P. Casas, MD, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, UK. Email: juan.pablo-casas@lshtm.ac.uk

Keywords: ACE inhibitors; angiotensin receptor antagonists; antihypertensive drugs; clinical trials; end-stage renal disease

The first 10% of the full text of this article appears below.

In their editorial in the present issue, we note that Mann et al. have managed, for the second time, to overcome their stated reluctance to criticize others. In the current piece, they raise issues that they aired previously in a letter to the Lancet [1]. We will respond again to the arguments they raise, and would also like to make readers aware of some relevant points, so that they can put the methodological criticisms of our paper into context. Our work was submitted to the Lancet, where it underwent internal review, then external peer review by three experts, followed by a statistical review. No significant concerns were raised. Like all articles, ours may have . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?